The multifaceted functions of C/EBPα in normal and malignant haematopoiesis
Authors:
- 25 November 2015
- journal article
- review article
- Published by Springer Nature in Leukemia
- Vol. 30 (4) , 767-775
Abstract
The process of blood formation, hematopoiesis, depends upon a small number of hematopoietic stem cells (HSCs) that reside in the bone marrow (BM). Differentiation of HSCs is characterised by decreased expression of genes associated with self-renewal accompanied by a stepwise activation of genes promoting differentiation. Lineage branching is further directed by groups of cooperating and counteracting genes forming complex networks of lineage specific transcription factors. Imbalances in such networks can result in blockage of differentiation, lineage reprogramming and malignant transformation. CCAAT/Enhancer Binding Protein Alpha (C/EBPα) was originally identified 30 years ago as a transcription factor that binds both promoter and enhancer regions. Most of the early work focused on the role of C/EBPα in regulating transcriptional processes as well as on its functions in key differentiation processes during liver, adipogenic and hematopoietic development. Specifically, C/EBPα was shown to control differentiation by its ability to coordinate transcriptional output with cell cycle progression. Later, its role as an important tumour suppressor, mainly in acute myeloid leukaemia (AML), was recognised and has been the focus of intense studies by a number of investigators. More recent work has revisited the role of C/EBPα in normal hematopoiesis, especially its function in HSCs, and also started to provide more mechanistic insights into its role in normal and malignant hematopoiesis. In particular, the differential actions of C/EBPα isoforms, as well as its importance in chromatin modelling and cellular reprogramming, are beginning to be elucidated. Finally, recent work has also shed light on the dichotomous function of C/EBPα in AML by demonstrating its ability to act as both a tumour suppressor and promoter. In the present review, we will summarise the current knowledge on the functions of C/EBPα during normal and malignant hematopoiesis with special emphasis on the recent work.Keywords
This publication has 103 references indexed in Scilit:
- The role of mutations in epigenetic regulators in myeloid malignanciesNature Reviews Cancer, 2012
- Prognostic Relevance of Integrated Genetic Profiling in Acute Myeloid LeukemiaNew England Journal of Medicine, 2012
- Enhancer function: new insights into the regulation of tissue-specific gene expressionNature Reviews Genetics, 2011
- Simple Combinations of Lineage-Determining Transcription Factors Prime cis-Regulatory Elements Required for Macrophage and B Cell IdentitiesMolecular Cell, 2010
- Heterogeneity within AML with CEBPA mutations; only CEBPA double mutations, but not single CEBPA mutations are associated with favourable prognosisBritish Journal of Cancer, 2009
- IFNα activates dormant haematopoietic stem cells in vivoNature, 2009
- Direct Reprogramming of Terminally Differentiated Mature B Lymphocytes to PluripotencyCell, 2008
- C/EBPα:AP-1 leucine zipper heterodimers bind novel DNA elements, activate the PU.1 promoter and direct monocyte lineage commitment more potently than C/EBPα homodimers or AP-1Oncogene, 2007
- Tribbles homolog 2 inactivates C/EBPα and causes acute myelogenous leukemiaCancer Cell, 2006
- Transformation from committed progenitor to leukaemia stem cell initiated by MLL–AF9Nature, 2006